Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

29 januari 2021 uppdaterad av: University Hospital Tuebingen

An Open Label Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Nivolumab in Patients With Four and More Symptomatic Brain Metastases of Melanoma

Up to 50% of patients with unresectable metastatic melanoma will develop brain metastases during their lifetime. A possible treatment options for patients with brain metastases are surgery and radiotherapy but usually for lesions in the range of < 3 brain metastases. This study was performed to evaluate the addition of immune checkpoint inhibitors in patients with stage IV melanoma with > 3 symptomatic brain metastases, who are not eligible for surgery or radiosurgery.

Studieöversikt

Detaljerad beskrivning

Brain metastases are a frequent problem in patients with melanoma. Up to 50% of patients with unresectable metastatic melanoma will develop brain metastases during their lifetime with a median overall survival of 4 months. Surgical removal or stereotactic radiosurgery of brain metastases can improve overall survival in patients with a limited number of lesions, usually in the range of one to three brain metastases depending on neuroanatomical localization. This benefit is no longer present when considering patients with > 3 brain metastases. As cytotoxic chemotherapy and multiple chemotherapeutic agents show only limited activity in > 3 brain metastases patients, immune checkpoint inhibitors such as ipilimumab and nivolumab offer new opportunities to improve disease outcomes for these patients.

This open label phase II study evaluates safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with stage IV melanoma with four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgery.

Studietyp

Interventionell

Inskrivning (Faktisk)

6

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Buxtehude, Tyskland
        • Elbe Kliniken Stade - Buxtehude GmbH
      • Dresden, Tyskland
        • Universitätsklinik Carl Gustav Carus Dresden
      • Erfurt, Tyskland
        • Helios Klinikum Erfurt
      • Essen, Tyskland
        • Universitätsklinikum Essen
      • Heidelberg, Tyskland
        • Universitatsklinikum Heidelberg
      • Ludwigshafen, Tyskland
        • Gesellschaft für Klinische Forschung Ludwigshafen mbH
      • Mannheim, Tyskland
        • Universitätsklinikum Mannheim
      • München, Tyskland
        • Klinikum rechts der Isar
      • Quedlinburg, Tyskland
        • Harzklinikum Dorothea Christiane Erxleben GmbH
      • Regensburg, Tyskland
        • Universitätsklinikum Regensburg
      • Tübingen, Tyskland
        • Universitatsklinikum Tubingen

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Signed informed consent (ICF) prior to any screening procedures being performed
  • Ability to comply with protocol requirements
  • Metastatic histologically confirmed melanoma that is unresectable
  • Presence of > 3 active brain metastases confirmed/evaluated by MRI
  • Measurable disease by MRI per iRANO and RECIST 1.1 criteria
  • The time between the baseline MRI and the date of registration should not exceed 28 days. Steroid treatment is permissible before brain MRI evaluation but the dose should have been stable for at least 7 days and should be carefully documented
  • Patient must agree to the cerebro-spinal fluid (CSF) collections according to the study protocol
  • Patients naïve for systemic treatment are eligible
  • Patients pretreated with systemic immunotherapy, targeted therapy or chemotherapy are eligible (exception: previous treatment with the combination of CTLA-4 and PD-1 antibodies)
  • Patients must have recovered completely from any treatment-related acute toxicity associated with prior therapy
  • At least two weeks must have passed since the last systemic anti-cancer treatment
  • Patients with prior local therapy of brain metastases are eligible
  • Patients may have received irradiation therapies: A) None; B) Whole brain irradiation only, C) Stereotactic irradiation of single or few metastases, D) Combined B+C)
  • Screening laboratory values within 14 days prior to registration must meet the criteria: WBC ≥ 2,000/μL, Neutrophils ≥ 1,500/μL, Platelets ≥ 100 x103/μL, Hemoglobin > 9.0 g/dL, Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min, AST/ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL), INR ≤ 1.5
  • ECOG Performance Status 0, 1 or 2
  • Expected life expectancy of ≥ 3 months
  • Males and females ≥ 18 years old
  • Negative serum pregnancy test within 24 hours prior to the start of study drug for women of childbearing potential (WOCBP)
  • Women must not be breastfeeding
  • WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for 23 weeks after the last dose of investigational drug
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for a period of 31 weeks after the last dose of investigational drug. In addition, male patients must be willing to refrain from sperm donation during this time
  • Azoospermic males are exempt from contraceptive requirements. WOCBP who are permanently not heterosexually active are also exempt from contraceptive requirements, but must still undergo pregnancy testing as previously described.
  • Patients must agree to use at least two methods of contraception, with at least one highly effective method as listed in the ICF

Exclusion Criteria:

  • Diagnosed ocular melanoma
  • Previous systemic therapy with the combination of CTLA-4 and PD-1 antibodies
  • Use of any investigational or non-registered product within the 30 days before registration in the study
  • Prior active malignancy within the previous 3 years except locally curable cancers that have been apparently cured, such as: basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, or breast
  • History of organ transplantation
  • Active infection requiring systemic therapy
  • Active, known or suspected autoimmune disease (exceptions: patients with controlled Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment).
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Any serious or uncontrolled medical disorders thatmay increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive protocol therapy, or interfere with the interpretation of study results in the opinion of the investigator
  • Known substance abuse or psychiatric disorders that would preclude cooperation with tany requirements of the trial
  • Legal incapacity or limited legal capacity
  • Administration of live, attenuated vaccine within 4 weeks prior to the start of study drug
  • Positive test for HBs Ag or HCV antibody
  • Known history of a positive test for HIV or known AIDS
  • Patients with known allergy or hypersensitivity to any of the study drugs or excipients
  • Patients with results of imaging or radiological examinations indicating increased cerebral pressure which would prevent lumbar puncture

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment Phase
Treatment phase is divided into the "Induction Phase" and "Maintenance Phase". During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only .
In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
Andra namn:
  • OPDIVO
In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
Andra namn:
  • YERVOY

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Intracranial Control Rate after 6 months of treatment
Tidsram: 6 months
Proportion of patients with complete intracranial responses (CR), partial intracranial responses (PR) or stable intracranial disease (SD) after 6 months of treatment.
6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall survival
Tidsram: 2 years
Number of patients who stay alive after 2 years.
2 years
Progression-free survival
Tidsram: 2 years
Number of patients without progression after 2 years.
2 years
Stereotactic irradiation or surgery of brain metastases after partial tumor remission
Tidsram: 2 years
Percentage of patients in whom stereotactic irradiation or surgery of all metastases becomes applicable after partial tumor remission.
2 years
Tolerability according to NCI-CTCAE-Criteria
Tidsram: 2 years
All adverse events of all grades.
2 years
Best Overall Response Rate with Complete Respone (CR)
Tidsram: 6 months
Percentage of patients with CR at six months of treatment.
6 months
Best Overall Response Rate with Partial Response (PR)
Tidsram: 6 months
Percentage of patients with PR at six months of treatment.
6 months
Cognitive function evaluation by standardized diagnostic procedures
Tidsram: 2 years
Systemic longitudinal neuropsychological evaluation to investigate the influence of therapy on cognitive performance will be performed by standardized diagnostic procedures.
2 years
Quality of life evaluation with RAND 36-Item Health Survey 1.0
Tidsram: 2 years
Quality of life assessment is evaluated with the RAND 36-Item Health Survey questionnaires which include physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Evaluation will be performed according to the manual.
2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Claus Garbe, Prof.Dr.med., University Hospital Tuebingen

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 april 2018

Primärt slutförande (Faktisk)

1 januari 2021

Avslutad studie (Faktisk)

1 januari 2021

Studieregistreringsdatum

Först inskickad

19 oktober 2018

Först inskickad som uppfyllde QC-kriterierna

31 oktober 2018

Första postat (Faktisk)

2 november 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 februari 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 januari 2021

Senast verifierad

1 oktober 2018

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera